Laxmi Organic Industries Limited has informed the Exchange about Transcript
LXCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 1.8 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Revenue declined ~4% YoY in Q1 FY26 despite 8% volume growth, with PAT at ₹214 million (3.1% margin vs 4.8% last year). Essentials grew 4% on 11% volume growth but was offset by 7% price decline (linked to lower acetic acid at ~₹340 vs FY24 average of ~₹450); Specialties declined 18% due to an anticipated agro AI product phase-out (~9% of sales) and deferred deliveries (~4%) shifting to H2. Ethyl acetate spreads fell to ~$120/MT, well below the 12-year ex-COVID average of $220-225. Capex deployment is on track with ₹680 crores of the ₹750 crore FY26 plan already spent; Dahej mechanical completion is targeted for end Q3/early Q4 FY26. Management is pursuing the Hitachi Energy SF6-replacement LOI (contract expected in Q2) within the existing ₹1,100 crore capex envelope, while the Lote Fluoro site targets 40-60% of peak revenues in FY26.
Near-term pressure on margins and revenues likely persists through Q2-Q3 FY26 given sub-₹120 spreads, Specialties product phase-out, and muted demand in coatings/agro. Management views current levels as cyclical bottom and flags potential upside from Chinese capacity moderation, Sipchem mothballing a 100,000 MT ethyl acetate plant, and tariff-driven rerouting. Stock may react cautiously as management declined to give explicit full-year FY26 or FY27 revenue/EBITDA guidance.